ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. and Portola Pharmaceuticals are working together to develop betrixaban, an oral anticoagulant now in Phase II clinical trials for the prevention of stroke in patients with atrial fibrillation, an irregular heart rhythm. Merck will pay Portola $50 million up front for an exclusive license to the Factor Xa inhibitor. Portola could receive as much as $420 million more if certain milestones are reached. Merck will take on all development costs, and Portola has kept an option to cofund Phase III trials in return for additional royalties. Earlier this year, Portola signed a similar $575 million deal with Novartis for another anticlotting candidate.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter